Free Trial
LON:SBTX

SkinBioTherapeutics Final Earnings Report

SkinBioTherapeutics logo
GBX 9.75 +0.05 (+0.52%)
As of 04/1/2026

SkinBioTherapeutics EPS Results

Actual EPS
-GBX 0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SkinBioTherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SkinBioTherapeutics Announcement Details

Quarter
Final
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SkinBioTherapeutics Earnings Headlines

Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
AIM Market Roundup: IQE, System1, SkinBioTherapeutics
SkinBioTherapeutics forced to reverse royalty income statement
See More SkinBioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SkinBioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SkinBioTherapeutics and other key companies, straight to your email.

About SkinBioTherapeutics

SkinBioTherapeutics (LON:SBTX), a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

View SkinBioTherapeutics Profile